Lys114

Site Information
ELAPLkSkMIyAssk SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 11321643
Available spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 )
Disease tissue studied:	gastric cancer ( 11 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , non-small cell lung cancer ( 1 , 2 , 3 , 6 , 7 , 8 , 9 , 10 , 12 , 13 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 6 , 7 , 10 ) , non-small cell large cell lung carcinoma ( 1 , 7 ) , non-small cell squamous cell lung carcinoma ( 13 ) , small-cell lung cancer ( 4 , 5 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 6 , 14 ) , Cal-12T (pulmonary) ( 2 ) , Calu-3 (pulmonary) ( 8 ) , DMS153 (pulmonary) ( 3 ) , DMS53 (pulmonary) ( 5 ) , DMS79 (pulmonary) ( 4 ) , HCC44 (pulmonary) ( 2 ) , HCC78 (pulmonary) ( 1 ) , HCC827 (pulmonary) ( 8 ) , lung ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , MKN-45 (gastric) ( 11 ) , NCI-H128 (pulmonary) ( 4 ) , NCI-H1299 (pulmonary) ( 7 ) , NCI-H1355 (pulmonary) ( 6 ) , NCI-H1417 (pulmonary) ( 4 ) , NCI-H1437 (pulmonary) ( 2 , 3 ) , NCI-H1650 (pulmonary) ( 8 ) , NCI-H1666 (pulmonary) ( 2 ) , NCI-H1703 (squamous) ( 13 ) , NCI-H1734 (pulmonary) ( 7 ) , NCI-H1781 (pulmonary) ( 1 ) , NCI-H1792 (pulmonary) ( 6 ) , NCI-H1944 (pulmonary) ( 7 ) , NCI-H1975 (pulmonary) ( 8 ) , NCI-H2073 (pulmonary) ( 3 ) , NCI-H209 (pulmonary) ( 3 , 4 ) , NCI-H2106 (pulmonary) ( 8 ) , NCI-H2228 (pulmonary) ( 1 , 10 ) , NCI-H23 (pulmonary) ( 6 ) , NCI-H2405 (pulmonary) ( 2 ) , NCI-H3122 (pulmonary) ( 1 , 9 ) , NCI-H3255 (pulmonary) ( 12 ) , NCI-H358 (pulmonary) ( 7 ) , NCI-H441 (pulmonary) ( 6 ) , NCI-H446 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H524 (pulmonary) ( 4 ) , NCI-H526 (pulmonary) ( 5 ) , NCI-H661 (pulmonary) ( 1 ) , NCI-H69 (pulmonary) ( 5 ) , NCI-H82 (pulmonary) ( 5 ) , NCI-H838 (pulmonary) ( 3 )

References
1	Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
11	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
14	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info